Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in the upcoming 29th Annual Piper Jaffray Healthcare Conference in New York, NY.
Linthwaite will take part in a fireside chat presentation on Tuesday, November 28, 2017, at 4:30 pm ET at the Lotte New York Palace Hotel.
A live webcast of the company’s presentation and subsequent replay may be accessed at http://investors.fluidigm.com/events.cfm. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact:
Fluidigm Corporation
Ana Petrovic
Director, Corporate Development and Investor Relations
650 243 6628 (Office)
[email protected]
